Cancer biology is increasingly revealing that tumors are not defined solely by rapidly dividing malignant cells. They are dynamic ecosystems in which cancer cells, immune cells, blood vessels, connective-tissue cells and damaged or aging cells exchange signals that can determine whether a tumor remains controlled or becomes invasive. A new article by Zhao, Zhang, Li and colleagues examines one of the most complex relationships in this ecosystem: the interaction between cellular senescence and the immune microenvironment. Published in Cell Death Discovery, the study connects mechanisms observed across many cancer types with potential implications for glioblastoma, one of the most aggressive and treatment-resistant brain tumors.
Cellular senescence is a state in which a cell permanently stops dividing while remaining metabolically active. It is not the same as cell death. Senescence can arise when cells experience extensive DNA damage, oncogene activation, oxidative stress, shortened telomeres or exposure to cancer therapies. In healthy tissues, this response can act as a protective barrier by preventing damaged cells from continuing to proliferate. A senescent cell may also release signals that attract immune cells, allowing the immune system to identify and remove it. However, when senescent cells accumulate or escape immune clearance, the same biological program can become a source of chronic inflammation and tissue dysfunction.
The reason lies partly in the senescence-associated secretory phenotype, commonly known as SASP. Senescent cells can secrete inflammatory cytokines, chemokines, growth factors, proteases and other molecules that alter neighboring cells. Among the best-known signaling factors are interleukin-6 and interleukin-8, although the composition of SASP varies according to the cell type, the original stress and the surrounding tissue. These secretions can remodel the extracellular matrix, stimulate the recruitment of immune cells and influence blood-vessel formation. In a tumor, such signals may create conditions that support malignant-cell survival, invasion and resistance to treatment, even when the senescent cells themselves are no longer dividing.
The article presents senescence as a context-dependent process rather than an inherently beneficial or harmful event. Senescent cancer cells may stop proliferating temporarily after chemotherapy or radiation, but some can later escape this state or develop altered properties that contribute to relapse. Senescent stromal cells, including fibroblasts and endothelial cells, can also modify the tumor’s physical and chemical environment. Their secreted factors may increase tissue stiffness, disrupt normal barriers and provide cancer cells with signals that promote migration. At the same time, senescence can stimulate immune recognition, meaning that the outcome depends on whether immune surveillance is effective, suppressed or redirected by the tumor.
The immune microenvironment is therefore central to the story. Cytotoxic T lymphocytes and natural killer cells can recognize and eliminate stressed or senescent cells, while macrophages and other innate immune populations participate in their removal. Yet tumors frequently develop mechanisms that weaken these responses. Persistent SASP signaling may attract immunosuppressive macrophages, regulatory T cells or myeloid-derived suppressor cells, populations that can restrain effective anti-tumor immunity. Inflammatory signals may also produce immune exhaustion, a condition in which T cells remain present but gradually lose their ability to attack malignant cells. The result can be an environment where senescent cells survive long enough to influence tumor progression.
These interactions help explain why therapies designed to induce senescence produce mixed results. Forcing cancer cells into a non-dividing state can limit tumor expansion, but the remaining senescent population may continue releasing biologically active molecules. This has led to interest in “senolytic” strategies, which aim to selectively eliminate senescent cells, and “senomorphic” approaches, which attempt to suppress harmful SASP signaling without necessarily killing the cells. Neither strategy is universally applicable. Senescent cells can have different molecular profiles, and removing them indiscriminately could interfere with tissue repair or beneficial anti-tumor responses. The review emphasizes that treatment design will likely require identifying which senescent populations are present, what signals they produce and how immune cells respond to them.
The pan-cancer perspective is important because senescence and immunity do not behave identically in every malignancy. The same cytokine can have different effects depending on the tumor’s genetic background, tissue of origin and immune composition. In some cancers, senescence may strengthen immune surveillance and make malignant cells more visible to the immune system. In others, the accumulation of senescent stromal or immune cells may create a persistent inflammatory niche that favors tumor growth. Molecular features such as p53 and p16 pathways, DNA-damage responses, metabolic changes and chromatin remodeling can influence whether a cell enters stable senescence, undergoes apoptosis or adopts a reversible quiescent state. Distinguishing these states is essential because they may appear similar but require different therapeutic interventions.
The implications are particularly significant for glioblastoma. This brain tumor grows rapidly, infiltrates surrounding tissue and often returns despite surgery, radiation and chemotherapy. The central nervous system also contains a specialized immune environment shaped by the blood–brain barrier, resident microglia and restricted immune-cell trafficking. In glioblastoma, senescent tumor cells and senescent cells in the surrounding neural and vascular compartments could contribute to a microenvironment that supports invasion and treatment resistance. SASP factors may influence microglial behavior, alter communication between tumor cells and blood vessels, and promote inflammatory conditions that do not translate into effective tumor destruction. These possibilities make senescence–immune interactions a potentially important component of glioblastoma biology, although they also underline the need for disease-specific evidence.
A major message of the research is that future cancer treatment may need to target communication networks rather than isolated cell populations. Combining therapies that induce senescence with immune checkpoint inhibitors, senolytics or SASP-modulating drugs could theoretically produce stronger responses than any one approach alone. However, such combinations could also increase toxicity, provoke damaging inflammation or eliminate immune cells that are needed for tumor control. Reliable biomarkers will be required to determine the senescence state of individual tumors, measure SASP activity and identify immune populations that are helping or hindering treatment. Single-cell sequencing, spatial transcriptomics and advanced imaging could allow researchers to map these interactions directly inside tumors instead of treating the microenvironment as a uniform entity.
By linking broad cancer mechanisms with glioblastoma, Zhao and colleagues place cellular senescence within a larger view of tumor evolution: cancer progression is shaped not only by mutations that drive malignant growth, but also by the signals exchanged among damaged, aging, immune and cancerous cells. The review does not present senescence as a simple switch between protection and harm. Instead, it describes a changing biological state whose consequences depend on timing, location and immune context. Understanding that network could help researchers design therapies that preserve the protective functions of senescence while preventing its inflammatory and immunosuppressive effects. For glioblastoma and other difficult-to-treat cancers, that distinction may become central to turning the tumor microenvironment from an ally of disease into an obstacle to progression.
Subject of Research: Cellular senescence, the immune microenvironment, pan-cancer tumor progression and implications for glioblastoma.
Article Title: Interconnected roles of cellular senescence and the immune microenvironment in tumor progression: from pan-cancer mechanisms to glioblastoma implications
Article References:
Zhao, W., Zhang, P., Li, L. et al. Interconnected roles of cellular senescence and the immune microenvironment in tumor progression: from pan-cancer mechanisms to glioblastoma implications. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03284-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03284-8
Keywords: Cellular senescence, senescence-associated secretory phenotype, immune microenvironment, tumor progression, glioblastoma, cancer immunology, SASP, senolytics, immune surveillance, tumor biology
